Causey A G, Hill H M, Phillips L J
Bioanalytical Department, Hazleton UK, North Yorks.
J Pharm Biomed Anal. 1990;8(8-12):625-8. doi: 10.1016/0731-7085(90)80092-4.
Results from bioanalytical analyses for registration of a new drug entity are used to define its pharmacokinetics and bioavailability/bioequivalence. Whilst analytical data may be derived from the application of a validated method, it is essential to apply mathematical criteria to its acceptance, in order that the analyst can be assured that the assay is performing within defined limits and to its validated specification. Parameters evaluated for acceptability are the batch calibration curve, the minimum quantifiable concentration and the quality control (QC) sample acceptability. Specifically, six QC samples per analytical batch are used, two samples at each of three concentrations. The rationale for the definition of these criteria is evaluated together with a consideration of their applications and limitations. The relevance and use of Shewhart and Cusum plots to monitor assay performance is illustrated.
用于新药实体注册的生物分析分析结果用于定义其药代动力学和生物利用度/生物等效性。虽然分析数据可能来自经过验证的方法的应用,但应用数学标准来接受它是至关重要的,以便分析师能够确保该分析在规定的限度内运行并符合其验证规范。评估可接受性的参数是批次校准曲线、最低可定量浓度和质量控制(QC)样品的可接受性。具体而言,每个分析批次使用六个QC样品,在三个浓度下各有两个样品。这些标准定义的基本原理连同对其应用和局限性的考虑一起进行评估。说明了使用休哈特图和累积和图来监测分析性能的相关性和用途。